Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Devasis Panda

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Journal for Immunotherapy of Cancer|May 23, 2020
Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapyPrashant Ramesh Tembhare, Harshini Sriram, Twinkle Khanka, et al.
Cytometry. Part B, Clinical Cytometry|September 8, 2020
Immunophenotypic shift in the B-cell precursors from regenerating bone marrow samples: A critical consideration for measurable residual disease assessment in B-lymphoblastic leukemiaGaurav Chatterjee, Harshini Sriram, Sitaram Ghogale, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 13, 2025
Delphi Survey on Measurable Residual Disease in Multiple Myeloma: Prevailing Practices and the Way Forward in IndiaSmeeta Gajendra, Tanima Dwivedi, Karthik Bommannan, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Journal for Immunotherapy of Cancer|May 23, 2020
Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapyPrashant Ramesh Tembhare, Harshini Sriram, Twinkle Khanka, et al.
Cytometry. Part B, Clinical Cytometry|September 8, 2020
Immunophenotypic shift in the B-cell precursors from regenerating bone marrow samples: A critical consideration for measurable residual disease assessment in B-lymphoblastic leukemiaGaurav Chatterjee, Harshini Sriram, Sitaram Ghogale, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 13, 2025
Delphi Survey on Measurable Residual Disease in Multiple Myeloma: Prevailing Practices and the Way Forward in IndiaSmeeta Gajendra, Tanima Dwivedi, Karthik Bommannan, et al.
Pageof 3